ライフサイエンスコーパス: replacement therapy

1 placement therapy (RRT; also known as kidney replacement therapy).

2 s for a potential type 1 diabetes (T1D) cell replacement therapy.

3 ction with the purpose of facilitating tooth replacement therapy.

4 atric complications associated with dopamine replacement therapy.

5 to reverse this disease model with NPC1 gene replacement therapy.

6 ave thus far prevented development of enzyme replacement therapy.

7 ivity in patients requiring continuous renal replacement therapy.

8 ill patients treated with continuous kidney replacement therapy.

9 h severe acute kidney injury requiring renal replacement therapy.

10 30% or more from baseline, or chronic renal replacement therapy.

11 ong post-menopausal women not taking hormone replacement therapy.

12 reening tool or ultimately as part of a cell replacement therapy.

13 ibiotic doses often used in continuous renal replacement therapy.

14 (E2) treatment in a model of human estrogen replacement therapy.

15 d 0.75 (0.39-1.44; p=0.39) for chronic renal replacement therapy.

16 dney injury patients with the need for renal replacement therapy.

17 n, none have shown efficacy apart from renal replacement therapy.

18 tential cardiovascular risks of testosterone replacement therapy.

19 acute kidney injury courses requiring renal replacement therapy.

20 y injury during prolonged intermittent renal replacement therapy.

21 e in ICU patients requiring continuous renal replacement therapy.

22 acute kidney injury with the need for renal replacement therapy.

23 e the therapeutic efficacy of MPS IVA enzyme replacement therapy.

24 mice on methionine-restricted diet or enzyme replacement therapy.

25 amylin, and holds promise as a dual-hormone replacement therapy.

26 rs limits broadened application of beta-cell replacement therapy.

27 ther their incidence is increased by hormone replacement therapy.

28 kidney disease event as initiation of kidney replacement therapy.

29 surgery without requiring pancreatic enzyme replacement therapy.

30 jury and may be worsened by the use of renal replacement therapy.

31 ul as a trigger to initiate continuous renal replacement therapy.

32 ributing to the development of an LPL enzyme replacement therapy.

33 3 days before the start of continuous renal replacement therapy.

34 iratory support, and five and nine for renal replacement therapy.

35 Nineteen patients required renal replacement therapy.

36 nd is often associated with a need for renal replacement therapy.

37 ety and efficacy of asfotase alfa, an enzyme replacement therapy.

38 vitro disease modeling and personalized cell replacement therapy.

39 ictive therapy and decisions regarding renal replacement therapy.

40 removal using ultrafiltration during kidney replacement therapy.

41 readily treatable with oral thyroid hormone replacement therapy.

42 e of 45 to 60 seconds, for continuous kidney replacement therapy.

43 alf of all cases of kidney failure requiring replacement therapy.

44 luable for research and potentially for cell replacement therapy.

45 ved vasopressors and 79 (31%) received renal replacement therapy.

46 mortality probability and the need for renal replacement therapy.

47 decision of whether or not to initiate renal replacement therapy.

48 of digestive processes and pancreatic enzyme replacement therapies.

49 and found in oral contraceptives and hormone replacement therapies.

50 ock activity may provide an adjuvant in cell replacement therapies.

51 ted with potentially lactate-depleting renal replacement therapies.

52 mRNA-based regenerative medicine and protein replacement therapies.

53 ore effective and safe biomaterials for cell replacement therapies.

54 he feasibility of this novel device for cell replacement therapies.

55 approach for advancing ESC-to-RGC cell-based replacement therapies.

56 ights toward the development of future tooth replacement therapies.

57 29.5] ng/mL; P = 0.002), and need for renal replacement therapy (16.5 [11.3, 23.6] ng/mL vs. 25.1 [1

58 of mechanical ventilation (23.2%) and renal replacement therapy (6.6%) but the lowest rates of remde

59 During continuous renal replacement therapy, a high net ultrafiltration rate has

60 al failure were analyzed: the need for renal replacement therapy, acute kidney injury incidence, and

61 .33; 95% CI, 1.02-1.74; p = 0.03), and renal replacement therapy (adjusted odds ratio, 1.49; 95% CI,

62 o, 1.01; 95% CI, 1.00-1.03; p = 0.02), renal replacement therapy (adjusted odds ratio, 1.81; 95% CI,

63 AKI, or on the need for postoperative renal replacement therapy after adjustments for confounders.

64 is study was to examine whether delayed gene replacement therapy after the onset of peripheral neurop

65 umatic and non-traumatic AKI requiring renal replacement therapy (AKI-RRT).

66 arkinson's disease, both ON and OFF dopamine replacement therapy, along with 50 age-matched, healthy

67 Thus, a model of estrogen replacement therapy, although restoring spine density an

68 ble supply of functional beta cells for cell replacement therapies and disease modeling for diabetes.

69 Enzyme replacement therapies and pre-clinical studies on gene s

70 podocytes are relatively resistant to enzyme replacement therapy and are poorly replicating, with lit

71 me is important for their future use in cell replacement therapy and disease modeling.

72 However, diurnal variation, continuous renal replacement therapy and drug-interference could confound

73 g the duration of PD as a modality for renal replacement therapy and increasing patient morbidity and

74 ls and meta-analyses evaluating testosterone replacement therapy and its association with cardiovascu

75 is associated with a reduced need for renal replacement therapy and lower acute kidney injury incide

76 risk for falls do not benefit from dopamine replacement therapy and often result in long-term hospit

77 were thrombocytopenia at initiation of renal replacement therapy and platelet decrease following rena

78 These can form in traditional protein replacement therapy and represent a major complication o

79 the need for organ support, including renal replacement therapy and/or for inotrope(s) and/or vasopr

80 oxies (e.g., oral contraceptive use, hormone replacement therapy), and the assumption of linear relat

81 tilation, 81 (3.2%) were treated with kidney replacement therapy, and 553 (21%) died.

82 h as invasive mechanical ventilation, kidney replacement therapy, and death.

83 comes of AKI severity, requirement for renal replacement therapy, and mortality were also measured an

84 d clearance profiles during continuous renal replacement therapy, and this knowledge is important to

85 tion, frequency of vasopressor use and renal replacement therapy, and time to in-hospital clinical de

86 y of breast cancer, body mass index, hormone replacement therapy, and use of tobacco and alcohol.

87 thin 90 days; mechanical ventilation-, renal replacement therapy-, and vasopressor-free days within 2

88 te kidney injury receiving continuous kidney replacement therapy, anticoagulation with regional citra

89 ltration (UF(NET))) during continuous kidney replacement therapy are associated with increased mortal

90 The indication and timing of renal replacement therapy are controversially discussed.

91 date on the current transcatheter repair and replacement therapies, as well as a focused overview of

92 g] vs 28% [placebo]) and 1 trial of nicotine replacement therapy at 12 months (n = 257; 8.1% vs 8.2%)

93 Death or renal-replacement therapy at 30 days occurred to a similar ext

94 ardiogenic shock, the risk of death or renal-replacement therapy at 30 days, and mortality at 1 year

95 vely associated with the initiation of renal replacement therapy at admission.

96 a (Brineura), a tripeptidyl peptidase enzyme replacement therapy, became the first globally approved

97 tion-approved cessation medication (nicotine replacement therapy, bupropion, or varenicline).

98 A drug used in hormone replacement therapy can target estrogen receptors that h

99 onazole were cleared by the continuous renal replacement therapy circuit and clearance increased with

100 sfunction is a predictor of continuous renal replacement therapy circuit failure.

101 as connected to a pediatric continuous renal replacement therapy circuit programmed for a 10 kg child

102 An ex vivo continuous renal replacement therapy circuit was used to evaluate drug-ci

103 nts and from extracorporeal continuous renal replacement therapy circuits.

104 Continuous kidney replacement therapy (CKRT) can be a lifesaving intervent

105 e increased with increasing continuous renal replacement therapy clearance rates (7.66 mL/min, 4.97 m

106 not change with increasing continuous renal replacement therapy clearance rates.

107 lating with three different continuous renal replacement therapy clearance rates: 1) no clearance (0

108 min, respectively, for high continuous renal replacement therapy clearance).

109 be considered for current and upcoming gene replacement therapy clinical trials.

110 Median time to continuous renal replacement therapy commencement was 4 hours (interquart

111 jor abdominal surgery, use of HES for volume replacement therapy compared with 0.9% saline resulted i

112 atients with requirement of continuous renal replacement therapy (CRRT) represent a growing intensive

113 In patients receiving continuous renal replacement therapy (CRRT), the concentrations of the sa

114 epted surgical technique for subretinal gene replacement therapy delivery in pediatric patients exist

115 e defined as a composite of mortality, renal replacement therapy-dependence or inability to recover 5

116 Continuous renal replacement therapy did not decrease platelets compared

117 intermittent intracerebroventricular enzyme replacement therapy dosing with rhbeta-Gal is a tunable

118 A regimen of intermittent enzyme replacement therapy dosing with rhbeta-Gal, followed by

119 Renal replacement therapy during ICU stay and number of medica

120 n, days alive and free of vasopressor, renal replacement therapy during ICU stay, and length of ICU a

121 Here, an enzyme replacement therapy (ERT) approach in fibroblasts from G

122 Here, an enzyme replacement therapy (ERT) approach in fibroblasts from G

123 Ls) and brain infarctions and whether enzyme replacement therapy (ERT) changes this risk.

124 Cardiac response to enzyme replacement therapy (ERT) in Fabry disease is typically

125 Enzyme replacement therapy (ERT) is a standard therapeutic opti

126 Although enzyme replacement therapy (ERT) is considered standard of care

127 All patients should initially receive enzyme replacement therapy (ERT), followed by definitive treatm

128 ght depend on the prompt initiation of renal replacement therapy-especially when liver failure reduce

129 glomerular filtration rate (if not on renal replacement therapy) evaluated up to 90 days after disch

130 on of mechanical ventilation, need for renal replacement therapy, extracorporeal life support or card

131 o replace these lost cells include stem cell replacement therapy, few differentiated stem cells turn

132 connectivity.SIGNIFICANCE STATEMENT Estrogen replacement therapy following menopause or surgical remo

133 vel gene replacement, gene editing, and cell replacement therapies for cone dystrophies.

134 induced beta-cells or islets to advance cell replacement therapies for diabetes and in direct imaging

135 enewable cell sources holds promise for cell replacement therapies for diabetes.

136 ally ill patients requiring continuous renal replacement therapy for acute kidney injury.

137 nesis inhibitors, can be repurposed for TSP1 replacement therapy for CCMs.

138 evidence supporting best practices in renal replacement therapy for critically ill patients with acu

139 t stem cells (hPSCs) holds promise as a cell replacement therapy for diabetes.

140 e under active investigation as a dystrophin replacement therapy for DMD.

141 dosis, and the mucopolysaccharidoses; enzyme replacement therapy for fucosidosis, the mucopolysacchar

142 process could serve as an effective protein replacement therapy for LAMA2-CMD.

143 aminin-111 can serve as an effective protein-replacement therapy for LAMA2-CMD.

144 nties about the optimal application of renal replacement therapy for patients with acute kidney injur

145 It is still a challenge to develop gene replacement therapy for retinal disorders caused by muta

146 There is no doubt that renal replacement therapy for the most severe forms of acute k

147 he aim of this project was to develop a gene replacement therapy for treating Charcot-Marie-Tooth dis

148 utcomes 3 acute kidney injury received renal replacement therapy, for a median duration of 7 days (3-

149 , 60 days, and 1 year, renal recovery, renal replacement therapy free days, ICU-free days, and hospit

150 ary end points were 90-day mortality, kidney replacement therapy-free days, and ICU-free days.

151 .1% [95% CI, -6.5% to 8.8%]; P = .77; kidney replacement therapy-free days: 18.5 vs 18.2; difference,

152 Indices of continuous renal replacement therapy function representing 554,991 minute

153 These targeted therapies include enzyme replacement therapies, gene therapies targeting the brai

154 ired kidney function, albuminuria, and renal replacement therapy globally, thus placing a large burde

155 chanical ventilation, vasopressor use, renal replacement therapy, grade 3/4 hepatic encephalopathy, W

156 ute kidney injury requiring continuous renal replacement therapy, greater than 10% fluid overload was

157 linical indications for initiation of kidney replacement therapy had been enrolled.

158 Cell-replacement therapies have long been an attractive prosp

159 haemodialysis - an essential part of kidney replacement therapy - have remained unchanged for decade

160 tion of hemodynamic instability during renal replacement therapy helped to achieve ultrafiltration go

161 Future monitoring of continuous renal replacement therapy hemodynamics may facilitate remedial

162 Cell replacement therapies hold great therapeutic potential.

163 gene editing and messenger RNA-based protein replacement therapy hold tremendous potential to effecti

164 re is uncertainty about the role of hormonal replacement therapy (HRT) in the development of asthma.

165 treatment for POI during puberty is hormone replacement therapy (HRT), which delivers non-physiologi

166 ly, self-regulated insulin delivery and cell replacement therapies, hydrogels are employed to mitigat

167 by renal failure requiring continuous renal replacement therapy, hypertension (systolic blood pressu

168 ment in 23 (9.4%) versus 9 (3.7%), and renal replacement therapy in 148 (58.5%) versus 99 (39.1%).

169 on many areas of controversy regarding renal replacement therapy in acute kidney injury, providing a

170 llel-group trial of two strategies for renal replacement therapy in critically ill patients with acut

171 s first-line treatment for continuous kidney replacement therapy in critically ill patients, the evid

172 These data agree with the role for EGF replacement therapy in EGF-deficient individuals with AD

173 t stem cells (hPSCs) and its application for replacement therapy in end-stage renal disease have been

174 ls to properly clarify the role of vitamin D replacement therapy in HL.

175 bout the cognitive effects of early dopamine-replacement therapy in neurological disorders.

176 risk of acute kidney injury requiring renal replacement therapy in SOT vs. non-SOT patients (37% vs.

177 ngs do not support the use of HES for volume replacement therapy in such patients.

178 Nicotine replacement therapy in the form of transdermal nicotine

179 of these patients requiring continuous renal replacement therapy in the PICU.

180 ome, and acute kidney injury requiring renal replacement therapy in the two out of three patients.

181 rmed decisions when considering testosterone replacement therapy in their patients.

182 intensity, and duration of continuous renal replacement therapy in this setting are unknown.

183 Complications of renal replacement therapy include hemodynamic instability with

184 such as estrogens decrease CAD risk, hormone replacement therapy increases risk.

185 ized trials have suggested that testosterone replacement therapy increases the risk of cardiovascular

186 These findings suggest that continuous renal replacement therapy initiated early and continued or lon

187 rease from ICU admission to continuous renal replacement therapy initiation (p = 0.024).

188 e between ICU admission and continuous renal replacement therapy initiation was also associated with

189 decrease in platelet values following renal replacement therapy initiation was associated with incre

190 openia and platelet decrease following renal replacement therapy initiation were associated with incr

191 d balance from admission to continuous renal replacement therapy initiation, adjusted for body weight

192 r, independent of timing of continuous renal replacement therapy initiation, that should be further e

193 herapy and platelet decrease following renal replacement therapy initiation.

194 ter adjusting for timing of continuous renal replacement therapy initiation.

195 sed already 5 days prior to continuous renal replacement therapy initiation.

196 ute kidney injury requiring continuous renal replacement therapy is a serious treatment-related compl

197 egnancy through maternal smoking or nicotine replacement therapy is associated with adverse birth out

198 Acute kidney injury requiring renal replacement therapy is associated with high morbidity an

199 Continuous renal replacement therapy is associated with reduced ammonia c

200 Cell replacement therapy is emerging as a promising treatment

201 circuit interactions during continuous renal replacement therapy is essential for appropriate drug do

202 sk of mortality is high, especially if renal replacement therapy is needed.

203 Enzyme replacement therapy is one therapeutic option, but since

204 ansplant patients requiring continuous renal replacement therapy is sadly high.

205 erload at the initiation of continuous renal replacement therapy is the most important and earliest p

206 augmentative recombinant intravenous enzyme replacement therapy (IV-ERT) post transplantation.

207 The treatment options for ESKD are kidney replacement therapy (KRT) and conservative management.

208 diovascular events, and initiation of kidney replacement therapy (KRT).

209 kidney replacement therapy (NKRT) and kidney replacement therapies (KRTs, including peritoneal dialys

210 interventions are not recommended: oestrogen replacement therapy (Level A2) and acetylcholinesterase

211 l to 18 years old requiring continuous renal replacement therapy located in the ICU; 2) described phy

212 pital length of stays, requirement for renal replacement therapy, longer duration of mechanical venti

213 Continuous renal replacement therapy may help reduce ammonia levels.

214 nicotine found in smoking-cessation nicotine-replacement therapies, may have potential benefits on sm

215 xtracorporeal membrane of oxygenation, renal replacement therapy, mechanical ventilation, and/or ther

216 ntimicrobials in an ex vivo continuous renal replacement therapy model.

217 uded limb ischemia, bleeding, need for renal replacement therapy, multiorgan failure, stroke or trans

218 elines are lacking for the use of non-kidney replacement therapy (NKRT) and kidney replacement therap

219 Acute kidney injury requiring renal replacement therapy occurred in 20% of SOTr compared to

220 No differences in the need for renal replacement therapy, occurrence rate of myocardial ische

221 and its analogs had a reduced need for renal replacement therapy (odds ratio, 0.59 [0.37-0.92]; p = 0

222 risk group were more likely to require renal replacement therapy (odds ratio, 10.4; 95% CI, 5.9-18.1)

223 r nonseptic causes and 2) the need for renal replacement therapy (odds ratio, 4.89; 3.83-6.28), and f

224 cient delivery of messenger RNAs for protein replacement therapies offers great promise but remains c

225 ated in Parkinson's disease (PD) by dopamine replacement therapy, often with detrimental consequences

226 ll molecules, monoclonal antibodies, protein replacement therapies, oligonucleotides and gene and cel

227 e is known on the impact of continuous renal replacement therapy on antimicrobial dose requirements i

228 X chromosome genomic imprinting and hormone replacement therapy on brain development.

229 this study, we evaluate the effects of renal replacement therapy on subsequent platelet values, the p

230 eutic approaches beyond traditional dopamine replacement therapies.One of the biggest challenges in t

231 bal Outcomes 3 defined by the need for renal replacement therapy or changes in urine output, serum cr

232 Our primary endpoint was stage 3 AKI, renal replacement therapy or death within 7 days.

233 jury (serum creatinine > 354 umol/L or renal replacement therapy or minimum urine output < 0.3 mL/kg/

234 imic led to change in management (eg, enzyme replacement therapy) or family screening in all cases.

235 ard ratio for death from renal causes, renal replacement therapy, or doubling of the serum creatinine

236 ected by diurnal variation, continuous renal replacement therapy, or drugs.

237 th, stroke, myocardial infarction, new renal replacement therapy, or repeat revascularization.

238 a composite of in-hospital mortality, renal replacement therapy, or severe right ventricular failure

239 mechanical ventilation, vasopressors, renal replacement therapy, or vasodilator therapy.

240 idespread availability of safe and effective replacement therapy, patients with HA and HB continue to

241 at 7 days, the need for postoperative renal replacement therapy, postoperative red blood cell transf

242 days and acute renal failure requiring renal replacement therapy predicted prolonged critical illness

243 Replacement therapy, providing the missing coagulation f

244 However, no trials of testosterone replacement therapy published to date were designed or a

245 Neuronal replacement therapies rely on the in vitro differentiati

246 ant breast cancer (BC) treatment and hormone replacement therapy remains a priority.

247 Continuous renal replacement therapy renin removal was negligible (mass c

248 of HUS (primary outcome) and need for renal replacement therapy (RRT) (secondary outcome) in STEC-in

249 independent predictor of the need for renal replacement therapy (RRT) in the first month post-LT.

250 unity to characterize the incidence of renal replacement therapy (RRT) initiation over the life cours

251 lthough lifesaving in many situations, renal replacement therapy (RRT) may be associated with complic

252 at 7 days, the need for postoperative renal replacement therapy (RRT), postoperative red blood cells

253 nit admission (69%), intubation (65%), renal replacement therapy (RRT; 33%), and mortality (42%).

254 ficant reduction in the requirement of renal replacement therapy (RRT; 56.6% vs. 80%; P = 0.006) and

255 to acute kidney injury (AKI) requiring renal replacement therapy (RRT; also known as kidney replaceme

256 Acute renal replacement therapies (RRTs), including ultrafiltration,

257 Five independent continuous renal replacement therapy runs were performed to assess inter-

258 t a total of 78 prolonged intermittent renal replacement therapy sessions, 39 in each arm.

259 these interventions and/or continuous renal replacement therapy-specific deliverables was inconsiste

260 Surfactant Replacement Therapy (SRT), which involves instillation o

261 ease modelling, and examining novel cellular replacement therapy strategies.

262 Acute Renal Failure Trial Network and RENAL Replacement Therapy Study Investigators trials.

263 Acute Renal Failure Trial Network and RENAL Replacement Therapy Study trials were used.

264 provides a proof of principle for viral gene replacement therapy targeted to Schwann cells to treat C

265 Regular immunoglobulin replacement therapy tended to stabilize lung function.

266 biology have allowed the development of cell-replacement therapies that comprise dopamine neurons der

267 nd the HPG axis-based treatments of estrogen replacement therapy, the progesterone derivative allopre

268 rence of acute kidney injury, need for renal-replacement therapy, time to target temperature, and neu

269 nto functional cardiomyocytes (CMs) for cell replacement therapy, tissue engineering, drug discovery

270 ring either intermittent or continuous renal replacement therapy) to $876,539 (data from an acute ren

271 association between the use of testosterone replacement therapy (TRT) and prostate cancer remains un

272 Administering T-replacement therapy (TRT) reverses many of the symptoms

273 luate the long-term impact of a novel enzyme replacement therapy [truncated human CBS C15S mutant mod

274 t requiring vasopressor and continuous renal replacement therapy tube disconnection, pooled occurrenc

275 We aimed to study continuous renal replacement therapy use in acute liver failure patients

276 or patient characteristics, continuous renal replacement therapy use, ammonia dynamics, and outcomes.

277 tion of mechanical ventilation, use of renal replacement therapy, use of vasopressors and inotropes,

278 enetic inner ear disorders, we designed gene replacement therapies using synthetic adeno-associated v

279 Continuous renal replacement therapy using blood flow rate set at 250 mL/

280 Renal replacement therapy variables, demographic, clinical, an

281 ality of patients requiring continuous renal replacement therapy was 54.4% (37/68 patients).

282 thrombocytopenia in patients requiring renal replacement therapy was associated with increased mortal

283 Renal replacement therapy was needed in 23% and inotropes(s) a

284 Continuous renal replacement therapy was not an independent predictor of

285 Continuous renal replacement therapy was performed in the hemodiafiltrati

286 amic support, respiratory support, and renal replacement therapy was reported in six of 15 randomized

287 enal failure study in which continuous renal replacement therapy was the most expensive therapy).

288 To develop a gene replacement therapy, we initially characterized the huma

289 1.86-23.08) at the start of continuous renal replacement therapy were associated with PICU mortality.

290 uable patients who received continuous renal replacement therapy were included.

291 nt patients receiving regular immunoglobulin replacement therapy were tested for HEV RNA and anti-HEV

292 ffective for smoking cessation than nicotine-replacement therapy, when both products were accompanied

293 Recombinant bioengineering has led to replacement therapies with easier modes of administratio

294 that could signal a new class of factor VIII replacement therapy with a weekly treatment interval.

295 jury undergoing prolonged intermittent renal replacement therapy with cooler dialysate experienced si

296 ccurrence and optimize the outcomes of tooth replacement therapy with dental implants in this specifi

297 omized to start prolonged intermittent renal replacement therapy with dialysate temperature of 35 deg

298 tions for NPC1 are few, and classical enzyme replacement therapy with the recombinant protein is not

299 d of a composite end point of death or renal-replacement therapy within 30 days and mortality within

300 use or severe renal failure leading to renal replacement therapy within 30 days.